ChAdOx1.HTI + MVA.HTI + GS-9620 + Placebo + Placebo Oral Tablet
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HIV/AIDS
Conditions
HIV/AIDS
Trial Timeline
Feb 20, 2020 → Dec 16, 2022
NCT ID
NCT04364035About ChAdOx1.HTI + MVA.HTI + GS-9620 + Placebo + Placebo Oral Tablet
ChAdOx1.HTI + MVA.HTI + GS-9620 + Placebo + Placebo Oral Tablet is a phase 2 stage product being developed by Gilead Sciences for HIV/AIDS. The current trial status is completed. This product is registered under clinical trial identifier NCT04364035. Target conditions include HIV/AIDS.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04364035 | Phase 2 | Completed |
Competing Products
11 competing products in HIV/AIDS
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Metformin | Merck | Phase 2/3 | 65 |
| Elvitegravir, Cobicistat, TAF, FTC + Efavirenz, TDF, and 3TC | Gilead Sciences | Pre-clinical | 22 |
| Switch to E/C/FTC/TAF daily | Gilead Sciences | Phase 1/2 | 40 |
| Biktarvy + Symtuza | Gilead Sciences | Phase 3 | 76 |
| Truvada | Gilead Sciences | Approved | 84 |
| bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) + Standard initiation of antiretroviral therapy (ART) | Gilead Sciences | Approved | 84 |
| Emtricitabine and Tenofovir | Gilead Sciences | Approved | 84 |
| TDF/FTC 300mg/200mg fixed-dose combination tablets + TAF/FTC 25mg/200mg fixed-dose combination tablets | Gilead Sciences | Phase 3 | 76 |
| Maraviroc | Pfizer | Phase 1 | 32 |
| Efavirenz | Bristol Myers Squibb | Pre-clinical | 22 |
| Moxifloxacin + Placebo + Efavirenz | Bristol Myers Squibb | Phase 1 | 32 |